A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

Trial Profile

A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Lintuzumab Ac-225 (Primary) ; Cytarabine; Furosemide; Spironolactone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 04 Oct 2017 According to an Actinium Pharmaceuticals media release, trial is now active at 16 clinical trials sites and a planned interim analysis is expected by the end of 2017 and top line data in the first half of 2018.
    • 13 Sep 2017 According to an Actinium Pharmaceuticals media release, updates from the study will be presented at the Society of Hematologic Oncology 2017 Annual Meeting (SOHO).
    • 15 Jun 2017 According to an Actinium Pharmaceuticals media release, currently there are twelve active clinical trial sites in this clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top